Johnson & Johnson $JNJ Shares Sold by Villere ST Denis J & Co. LLC

Key Points

• Villere ST Denis J & Co. cut its Johnson & Johnson stake by 5.2%, selling 5,575 shares in the third quarter; it still held 101,200 shares valued at about $26.8 million.
• J&J reported encouraging clinical updates across its drug pipeline, including Phase 3 progress for an oral psoriatic arthritis treatment and strong early prostate cancer responses, though the prostate cancer findings come from a small Phase 1 study.
• The company’s latest quarter slightly beat earnings and revenue estimates, with revenue up 5.9% year over year. Analysts’ average rating was “Moderate Buy,” with an average price target of $275.92.

Villere ST Denis J & Co. LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,200 shares of the company's stock after selling 5,575 shares during the period. Johnson & Johnson makes up 2.8% of Villere ST Denis J & Co. LLC's investment portfolio, making the stock its 11th largest holding. Villere ST Denis J & Co. LLC's holdings in Johnson & Johnson were worth $26,792,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. National Pension Service raised its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc boosted its stake in Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B grew its position in Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after purchasing an additional 2,563 shares during the last quarter. AMG Asset Management Group Inc. grew its position in Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock valued at $1,020,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after purchasing an additional 13,737 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Bank of America reaffirmed a "neutral" rating and issued a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. TD Cowen restated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Guggenheim reiterated a "buy" rating and set a $287.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $275.92.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

JNJ opened at $281.86 on Tuesday. The company's 50-day simple moving average is $266.18 and its two-hundred day simple moving average is $248.62. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a market capitalization of $678.53 billion, a P/E ratio of 42.71, a P/E/G ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the business posted $2.80 earnings per share. The business's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.